Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer

Lorraine Burke, Clare T. Butler, Adrian Murphy, Bruce Moran, William M. Gallagher, Jacintha O'Sullivan, Breandán N. Kennedy

Research output: Contribution to journalShort surveypeer-review

27 Scopus citations


Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.

Original languageEnglish (US)
Article number103
JournalFrontiers in Cell and Developmental Biology
Issue numberSEP
StatePublished - Sep 21 2016


  • Colorectal cancer
  • Cysteinyl leukotriene
  • Cysteinyl leukotriene receptor antagonist
  • Eicosanoid
  • Hallmarks of cancer
  • Tumorigenesis

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer'. Together they form a unique fingerprint.

Cite this